# Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects

> **NCT02224105** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 653048 BS
- **DRUG:** Prednisolone low
- **DRUG:** Prednisolone high
- **DRUG:** Placebo
- **DRUG:** sodium chloride infusion
- **DRUG:** endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)

## Key facts

- **NCT ID:** NCT02224105
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-05
- **Final completion:** —
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224105, "Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02224105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*